solubl
pselectin
rescu
mice
anthrax
lethal
toxininduc
mortal
pathwaymedi
correct
hemostasi
abstract
one
virul
factor
bacillu
anthraci
lethal
toxin
lt
induc
variou
pathogen
respons
includ
suppress
coagul
system
studi
observ
lt
markedli
increas
circul
solubl
pselectin
spsel
level
microparticl
mp
count
wildtyp
pselectin
psel
selp
psel
selplg
knockout
mice
spsel
induc
hypercoagul
state
pathway
gener
tissu
factorposit
mp
hypothes
increas
plasma
spsel
level
selfrescu
respons
host
ltmediat
suppress
coagul
system
agreement
hypothesi
result
indic
compar
wildtyp
mice
selp
selplg
mice
sensit
lt
addit
recombin
spsel
treatment
markedli
amelior
ltmediat
pathogenesi
reduc
mortal
result
elicit
circul
spsel
potenti
selfrescu
respons
benefici
host
recoveri
ltinduc
hypocoagul
state
result
suggest
administr
spsel
like
use
develop
new
strategi
treat
anthrax
anthrax
lethal
toxin
hemostasi
microparticl
solubl
pselectin
pselectin
ligand
anthrax
diseas
caus
gramposit
bacterium
bacillu
anthraci
caus
high
mortal
anim
human
lethal
toxin
lt
major
virul
factor
consist
protein
protect
antigen
pa
lethal
factor
lf
pa
bind
specif
cellular
receptor
form
membran
channel
mediat
entri
lf
target
cell
lf
metalloproteas
inhibit
mitogenactiv
protein
kinas
mapk
signal
pathway
proteolyt
inactiv
mapk
kinas
mek
symptom
anim
die
receiv
intraven
inject
purifi
lt
similar
anim
die
natur
infect
hemorrhag
one
major
manifest
observ
patient
experiment
anim
anthrax
human
hemorrhag
report
clinic
manifest
anthrax
type
includ
cutan
oropharyng
gastrointestin
inhal
anthrax
moreov
sever
hemorrhag
abnorm
hemorrhag
mediastin
hemorrhag
pneumon
submucos
hemorrhag
lesion
trachea
bronchi
observ
patient
lifethreaten
inhal
anthrax
hemorrhag
abnorm
probabl
caus
suppress
blood
coagul
system
addit
lt
caus
hemorrhag
hypoxiamedi
toxic
late
stage
infect
report
ltmediat
suppress
coagul
system
involv
reduct
platelet
megakaryocyt
function
suppress
hepat
express
coagul
factor
viii
fviii
part
similar
patholog
alter
observ
hemophilia
howev
low
platelet
count
mice
necessarili
lead
hemorrhag
unless
addit
complic
present
addit
low
plasma
fviii
level
hemorrhag
anim
inject
lt
amelior
supplementari
treatment
fviii
result
suggest
mechan
lt
suppress
coagul
investig
pselectin
psel
member
selectin
famili
primarili
local
membran
agranul
platelet
weibelpalad
bodi
endotheli
cell
activ
psel
transloc
cell
surfac
addit
membran
form
psel
also
express
solubl
form
may
aris
either
proteolyt
cleavag
andor
secret
altern
splice
isoform
increas
level
circul
solubl
psel
spsel
observ
thrombot
consumpt
disord
dissemin
intravascular
coagul
thrombot
thrombocytopen
purpura
involv
gener
hypercoagul
state
pathophysiolog
role
spsel
diseas
also
unclear
recombin
pseliggfc
fusion
protein
pselfc
treatment
mice
associ
procoagul
state
correct
hemostasi
mous
model
hemophilia
interact
psel
ligand
gener
procoagul
tissu
factor
tf
posit
microparticl
mp
studi
demonstr
lt
increas
circul
spsel
level
mice
although
mechan
spsel
induc
procoagul
state
remain
elus
increas
spsel
level
lttreat
mice
might
theoret
aid
host
surviv
hemorrhag
pathogenesi
therefor
hypothes
induct
circul
spsel
selfrescu
respons
mice
rebal
coagul
system
relev
regul
mechan
discuss
studi
report
hypox
tissu
injuri
may
involv
anthrax
ltmediat
toxic
mice
damag
hemorrhag
lung
caus
hypox
stress
mice
frequent
observ
patient
anim
anthrax
studi
ltinduc
lung
congest
hemorrhag
mice
fig
patreat
lttreat
associ
signific
plasma
leakag
fig
increas
plasma
spsel
level
fig
thrombocytopenia
fig
howev
control
protein
pa
induc
similar
pathogen
effect
moreov
observ
induct
plasma
spsel
associ
increas
circul
mp
count
fig
mp
submicroscop
mm
membran
vesicl
releas
variou
cell
includ
platelet
leukocyt
endotheli
cell
crucial
regul
coagul
system
investig
whether
enzymelink
immunosorb
assay
elisa
detect
spsel
signal
obtain
pselposit
mp
mous
plasma
mp
enrich
ultracentrifug
observ
spsel
enrich
mp
fraction
higher
signal
mp
vs
mppoor
plasma
mppp
although
supernat
fraction
mppp
plasma
low
spsel
level
still
approxim
fig
lower
signal
mppp
vs
mp
result
suggest
spsel
signal
plasma
detect
pselposit
mp
spsel
molecul
releas
cell
nonmpbound
form
circul
mp
contain
consider
spsel
level
recombin
spsel
increas
circul
mp
count
interact
psel
crucial
increas
mp
count
investig
whether
psel
essenti
ltmediat
increas
plasma
mp
count
examin
psel
gene
knockout
lttreat
lethal
dose
c
mice
h
pa
lt
treatment
lung
tissu
retain
evan
blue
level
indic
plasma
leakag
e
h
pa
lt
treatment
plasma
solubl
pselectin
spsel
level
mice
treat
pa
lt
h
shown
f
normal
salin
use
vehicl
treatment
e
f
quantifi
result
report
present
mean
standard
deviat
sd
n
ad
p
p
compar
respect
indic
group
n
ef
experi
replic
ko
selp
selplg
respect
mice
result
reveal
lt
significantli
increas
circul
mp
count
wildtyp
mice
selp
cc
selplg
c
c
psel
gene
ko
mice
fig
result
suggest
psel
essenti
ltmediat
increas
circul
mp
count
lt
elicit
rel
lower
count
circul
spsel
gene
ko
mice
wildtyp
mice
fig
wt
vs
ko
lt
group
express
part
involv
elicit
circul
spsel
level
increas
spsel
level
observ
certain
diseas
associ
platelet
abnorm
thu
plasma
spsel
consid
marker
platelet
dysfunct
moreov
recombin
psel
pselfc
treatment
induc
procoagul
state
increas
tfposit
mp
count
mice
lt
suppress
function
platelet
endotheli
cell
coagul
factor
induc
hemorrhag
hypothes
along
marker
platelet
disord
circul
spsel
may
also
play
pivot
role
activ
compens
defect
platelet
coagul
system
test
hypothesi
first
investig
effect
lt
pselfc
plasma
clot
time
vitro
vivo
follow
describ
previous
method
observ
vitro
treatment
lt
pselfc
min
affect
recalcif
plasma
clot
time
fig
suggest
reagent
directli
affect
activ
coagul
factor
short
treatment
contrast
treat
vivo
expect
lt
prolong
plasma
clot
time
pselfc
shorten
plasma
clot
time
fig
lt
pselfc
group
furthermor
pselfc
treatment
amelior
ltprolong
plasma
clot
mice
fig
panel
prolong
plasma
clot
time
mp
level
analyz
wild
type
psel
ko
mice
h
lt
treatment
plasma
spsel
level
analyz
wildtyp
ko
mice
h
lt
treatment
e
detect
spsel
level
psel
ko
mice
p
compar
respect
untreat
group
ab
de
p
compar
respect
pa
group
p
compar
respect
total
group
c
n
ae
treatment
normal
salin
use
vehicl
control
ce
usual
attribut
defect
coagul
system
exist
coagul
inhibitor
result
suggest
lt
exert
suppress
role
wherea
pselfc
exert
enhanc
role
plasma
clot
studi
report
procoagul
effect
pselfc
treatment
may
contribut
gener
tfposit
mp
therefor
rel
tfposit
mp
count
determin
flow
cytometri
fig
observ
pselfc
markedli
increas
tfposit
mp
count
wildtyp
mice
receiv
lt
treatment
fig
wt
group
panel
vs
panel
respect
contrast
pselfc
markedli
increas
tfposit
mp
count
gene
ko
mice
fig
ko
group
panel
vs
panel
respect
examin
whether
pselfc
may
also
compet
lt
lt
receptor
interact
thu
result
rescu
use
cytotox
assay
macrophag
use
describ
previous
method
data
suggest
antipa
ig
pselfc
control
protein
bovin
serum
albumin
bsa
rescu
ltinduc
macrophag
death
fig
indic
pselfc
inhibit
lt
activ
direct
competit
cellular
receptor
result
suggest
amelior
effect
pselfc
ltsuppress
plasma
clot
part
mediat
increas
circul
tfposit
mp
count
fig
addit
essenti
pselfcmedi
induct
tfposit
mp
accord
hypothesi
spsel
activ
releas
host
counteract
hemorrhag
abnorm
theoret
compar
wildtyp
mice
psel
ko
mice
sensit
lt
treatment
contain
spsel
releas
similarli
spsel
requir
function
increas
tfposit
mp
count
ko
mice
sensit
compar
parent
strain
lt
fact
psel
ko
mice
inde
die
rapidli
lethal
dose
lt
treatment
mgml
therefor
observ
clearer
rescu
use
ld
dose
lt
mgkg
wildtyp
mice
treat
psel
ko
mice
agreement
hypothesi
observ
lt
induc
markedli
higher
mortal
psel
ko
mice
wildtyp
mice
fig
result
suggest
psel
requir
mice
resist
ltmediat
toxic
pselfc
treatment
rebal
procoagul
tfposit
mp
count
lt
treatment
fig
panel
vs
complement
defect
fviii
markedli
amelior
ltinduc
pathogenesi
reduc
mortal
spsel
treatment
improv
hemostasi
mice
fviii
defici
mous
model
hemophilia
prompt
us
investig
potenti
rescu
effect
pselfc
treatment
ltinduc
pathogen
abnorm
plasma
leakag
thrombocytopenia
fig
fig
decreas
hematocrit
count
liver
damag
mice
treat
pselfc
h
lethal
dose
lt
administ
result
reveal
pselfc
treatment
markedli
amelior
aforement
ltmediat
pathogen
abnorm
fig
experiment
outlin
result
suggest
pselfc
treatment
success
reduc
anthrax
ltmediat
pathogenesi
patient
furthermor
investig
effect
pselfc
treatment
ltinduc
mortal
observ
pselfc
isotyp
control
ig
treatment
consider
reduc
mortal
mice
fig
although
ltinduc
mortal
mice
involv
induct
proinflammatori
cytokin
tnfa
lt
elicit
inflammasom
activ
eicosanoid
respons
manner
mice
antipsel
neutral
antibodi
recombin
spsel
amelior
inflamm
blockag
leukocyt
psel
psel
ligand
interact
inflam
tissu
antipsel
ig
show
amelior
effect
previou
report
use
viper
venomchalleng
mous
model
antipsel
ig
amelior
snake
venominduc
inflamm
coagul
defect
mortal
investig
whether
antiinflamm
properti
spsel
also
involv
rescu
examin
effect
antipselneutr
antibodi
treatment
antipselneutr
antibodi
recombin
spsel
suppress
inflamm
block
leukocyt
infiltr
inflam
tissu
psel
psel
ligand
interact
observ
similar
control
ig
antipselneutr
antibodi
rescu
lttreat
mice
fig
statist
signific
differ
control
ig
vs
antipsel
ig
suggest
rescu
effect
pselfc
like
mediat
inhibit
inflamm
final
rescu
effect
pselfc
b
anthraci
spore
evalu
although
condit
yet
optim
observ
singl
dose
pselfc
rescu
mice
challeng
b
anthraci
spore
fig
p
pselfc
vs
albumin
control
ig
group
collect
result
indic
lt
increas
circul
spsel
level
increas
spsel
level
benefici
role
surviv
anthrax
infect
increas
circul
spsel
level
associ
variou
cardiovascular
disord
includ
hypertens
coronari
arteri
diseas
atherosclerosi
atrial
fibril
addit
increas
spsel
level
observ
coagul
disord
infecti
diseas
cancer
accordingli
increas
plasma
spsel
level
consid
diseas
marker
widespectrum
diseas
involv
endotheli
damag
invivo
platelet
activ
thrombosi
find
suggest
patholog
role
neg
effect
spsel
moreov
physiolog
role
endogen
spsel
mainten
homeostasi
rare
discuss
studi
report
inject
artifici
prepar
recombin
spsel
benefici
recov
hypocoagul
state
mice
hemophilia
effect
like
spsel
pathwaymedi
enhanc
coagul
addit
also
shown
increas
level
circul
spsel
play
protect
role
mice
hemorrhag
hypox
stress
therefor
increas
endogen
spsel
level
may
theoret
physiolog
role
protect
hemorrhag
ischem
condit
correct
hemostasi
moreov
increas
spsel
level
observ
variou
hemorrhag
diseas
dengu
hemorrhag
fever
immun
thrombocytopenia
subarachnoid
hemorrhag
howev
role
spsel
disord
remain
elus
hemorrhag
one
major
manifest
anthrax
b
anthraci
virul
factor
lt
induc
coagul
defect
ischemia
hemorrhag
hemorrhag
ischem
pathogenes
part
mediat
suppress
coagul
factor
platelet
megakaryocyt
red
blood
cell
endotheli
cell
studi
observ
increas
spsel
level
selfrescu
respons
host
benefici
host
amelior
ltmediat
hemorrhag
agreement
hypothesi
observ
recombin
spsel
treatment
markedli
amelior
ltinduc
pathogenesi
reduc
mortal
mice
similar
regul
spsel
increas
plasma
mp
count
report
variou
hemorrhag
cardiovascular
disord
platelet
endotheli
cell
major
cell
type
express
psel
vivo
platelet
mp
abund
mp
bloodstream
constitut
circul
mp
circul
mp
express
consider
spsel
level
fig
observ
increas
level
nativ
plasma
spsel
mpbound
fraction
nonmpbound
fraction
mp
mppp
pa
vs
lt
fig
recombin
pselfc
treatment
still
markedli
amelior
lt
toxic
mice
fig
data
suggest
nonmpbound
plasma
spsel
molecul
adequ
correct
hemostasi
howev
figur
plasma
leakag
blood
paramet
reveal
pselmedi
rescu
experiment
outlin
evalu
amelior
pa
lt
mgkg
treatmentinduc
pathogenesi
effect
pselfc
pretreat
compar
control
ig
treatment
lung
retain
evan
blue
b
platelet
count
c
hematocrit
count
serum
aspart
aminotransferas
ast
level
e
mice
record
h
h
treatment
pa
lt
p
p
vs
respect
pa
c
control
ig
group
p
signific
amelior
vs
respect
lt
c
control
ig
group
n
mous
draw
use
report
origin
publish
blood
huang
hs
et
al
american
societi
hematolog
reproduc
permiss
hsinhou
chang
permiss
reus
must
obtain
rightshold
relationship
mpbound
nonmpbound
psel
plasma
requir
investig
basal
count
mp
ltinduc
mp
lower
selp
mice
wildtyp
mice
fig
suggest
psel
crucial
increas
circul
mp
count
addit
observ
crucial
spsel
gener
tfposit
mp
elicit
procoagul
state
suggest
involv
interact
psel
amelior
lt
toxic
accordingli
propos
hypothet
model
spselmedi
amelior
lt
toxic
fig
first
ltinduc
stress
increas
spsel
level
fig
pathway
spsel
increas
circul
tfposit
mp
count
induc
procoagul
state
amelior
ltmediat
hemorrhag
pathogenesi
fig
pseland
transfer
tf
mp
mediat
haematopoiet
cell
cell
tfposit
mpproduc
cell
model
fig
also
like
haematopoiet
lineag
cell
addit
psel
defici
greatli
enhanc
sensit
mice
lt
therefor
psel
along
anthrax
receptor
critic
factor
determin
suscept
mice
lt
reduction
approach
use
anthrax
lt
treatment
shown
induc
tnfaindepend
hypoxiamedi
toxic
mortal
mice
contrast
pathogenesi
real
anthrax
infect
complex
diseas
involv
virul
factor
edema
toxin
capsul
compon
display
higher
inflammatori
phenotyp
mix
procoagulantfibrinolyt
pictur
coagulopathi
anim
model
patient
notabl
studi
spsel
treatment
also
markedli
reduc
mortal
anthrax
sporechalleng
mice
fig
suggest
compar
spsel
rescu
lt
treatment
primarili
mediat
procoagul
properti
fig
spsel
like
exert
complex
role
rescu
anthrax
spore
challeng
inflammatori
mediat
induc
thrombosi
procoagul
respons
convers
antiinflammatori
treatment
amelior
hypercoagul
vasoocclus
vivo
regard
treatment
spsel
also
shown
induc
antiinflammatori
effect
previous
found
spsel
treatment
also
benefici
viper
venominduc
procoagulationassoci
hemorrhag
pathogenesi
mice
rescu
effect
hypercoagul
associ
antiinflammatori
properti
spsel
therefor
antiinflamm
effect
may
also
involv
spselmedi
rescu
lethal
infect
anthrax
spore
anthrax
complex
diseas
detail
mechan
associ
spselmedi
rescu
anthrax
spore
challeng
worthi
investig
howev
circul
spsel
level
elev
lt
spore
challeng
fig
fig
elicit
spsel
potenti
selfrescu
physiolog
respons
anthrax
infect
data
collect
suggest
spselmedi
enhanc
hemostasi
therapeut
implic
clinic
set
involv
defici
coagul
compar
coagulationsuppress
drug
coagul
cfumous
intraperiton
inject
lethal
dose
c
use
wildtyp
wt
mice
rescu
lt
spore
induc
mortal
h
pretreat
recombin
pselectin
iggfc
fusion
protein
pselfc
mgkg
c
antipselectin
ig
antipsel
ig
mgkg
b
compar
respect
control
ig
ac
bovin
serum
albumin
c
mortal
plot
kaplanmei
curv
ac
control
ig
vs
pselfc
p
albumin
control
ig
vs
pselfc
p
c
n
ab
spore
c
control
ig
group
c
experi
micegroup
n
pa
group
spore
c
pselfc
group
c
experi
micegroup
experi
micegroup
n
albumin
group
c
experi
micegroup
enhanc
agent
rare
develop
probabl
risk
thrombosi
therefor
effect
coagulationenhanc
agent
suitabl
treat
intern
hemorrhag
acut
phase
remain
unavail
previou
studi
report
lt
induc
acquir
fviii
defici
howev
treatment
addit
recombin
fviii
supplement
appear
effici
rescu
ltinduc
death
rescu
effici
fviii
treatment
ltinduc
mortal
lower
spsel
treatment
surviv
fig
vs
use
fviii
treatment
previou
report
therefor
major
compon
hemorrhageelicit
selfrescu
respons
spsel
may
use
develop
new
strategi
manag
hemorrhagerel
diseas
anthrax
chemic
purchas
sigmaaldrich
st
loui
mo
follow
describ
previous
method
polyclon
antipsel
ig
obtain
recombin
pseliggfc
fusion
protein
pselfc
immun
rabbit
antipsel
antibodi
isotyp
control
ig
purchas
bd
pharmingen
taiwan
taipei
taiwan
enzo
life
scienc
blossom
biotechnolog
taipei
taiwan
respect
pselfc
purchas
r
system
minneapoli
mn
b
anthraci
atcc
contain
plasmid
express
function
lt
edema
toxin
et
grown
blood
agar
plate
bap
maintain
brainheart
infus
broth
bhib
sigmaaldrich
st
loui
mo
usa
use
describ
previous
method
toxin
protein
protect
antigen
pa
lethal
factor
lf
purifi
b
anthraci
cultur
supernat
describ
previous
cultur
supernat
filtersteril
pass
filter
millipor
bedford
concentr
use
minitan
ultrafiltr
system
millipor
proteas
inhibitor
phenylmethylsulfonyl
fluorid
mm
sigmaaldrich
ad
prevent
toxin
degrad
ammonium
sulfat
ad
protein
precipit
collect
suspend
mm
tri
hydroxymethyl
aminomethan
tri
hcl
ph
extens
dialyz
buffer
purif
perform
fast
protein
liquid
chromatographi
fplc
mono
q
anion
exchang
pharmacia
piscataway
nj
mm
trishcl
ph
buffer
linear
mm
nacl
gradient
elut
min
pa
elut
mm
nacl
lf
elut
mm
nacl
lipopolysaccharid
lp
contamin
monitor
use
limulu
amoebocyt
lysat
qcl
kit
lonza
walkersvil
md
batch
purifi
lt
lp
contamin
level
less
eumg
lt
use
measur
spsel
level
use
elisa
kit
roch
diagnost
taipei
taiwan
accord
manufactur
instruct
rabbit
subcutan
inject
pa
mg
adjuv
mixtur
interv
cycl
antipa
antibodi
neutral
ltmediat
toxic
purifi
paimmun
rabbit
use
protein
column
ge
healthcar
life
scienc
taipei
taiwan
describ
previous
spore
b
anthraci
atcc
prepar
describ
previous
overnight
bhib
cultur
b
anthraci
dilut
approxim
colonyform
unit
cfu
ml
phosphatebuff
salin
aliquot
inocul
onto
blood
agar
plate
agar
plate
incub
c
phasebright
spore
observ
use
phasecontrast
light
microscopi
spore
harvest
wash
cold
steril
distil
ioniz
di
water
describ
previous
store
di
water
c
use
wk
water
chang
least
week
store
freezer
c
mo
qualiti
spore
determin
complementari
criteria
previous
establish
valid
presenc
dormant
spore
criteria
consist
evalu
absenc
veget
cell
rod
determin
microscop
examin
describ
ii
surviv
spore
hydrochlor
acid
n
wildtyp
pseldefici
selp
j
selplg
j
mous
strain
obtain
jackson
laboratori
bar
harbor
ko
mice
backcross
parent
mous
strain
least
gener
anthrax
lt
treatment
mice
induc
mark
discomfort
except
decreas
activ
initi
treatment
howev
decreas
activ
gener
phenomenon
appear
mice
includ
surviv
lt
treatment
suggest
decreas
activ
favor
predictor
death
measur
bodi
weight
h
lt
treatment
observ
signific
decreas
bodi
weight
lttreat
mice
suggest
mice
maintain
normal
food
water
uptak
level
treatment
spore
challeng
lethal
gener
progress
rapidli
intraperiton
inject
occur
within
hour
sudden
paralysi
handl
mice
narrow
time
window
difficult
surviv
mice
kill
co
follow
nation
institut
health
guidelin
end
experi
mortal
experi
mice
examin
everi
h
addit
death
observ
lt
treatment
surviv
mice
monitor
everi
day
mo
experiment
work
conduct
agreement
nation
taiwan
anim
protect
act
direct
protect
laboratori
anim
experiment
protocol
examin
experiment
anim
approv
anim
care
use
committe
tzuchi
univers
hualien
taiwan
approv
id
nation
defens
medic
center
taipei
taiwan
approv
id
intraven
retroorbit
treatment
control
ig
pselfc
antipsel
ig
perform
h
intraven
retroorbit
lt
challeng
mice
relev
reagent
intraven
inject
follow
dose
lt
mgkg
pselfc
mgkg
antipsel
ig
mgkg
isotyp
control
igg
mgkg
isotypematch
control
igg
use
control
protein
pselfc
experi
pselfc
iggfc
fusion
protein
tissu
sampl
prepar
mice
h
pa
lt
treatment
follow
describ
previous
method
sampl
fix
immers
neutral
buffer
formalin
dehydr
embed
paraffin
tissu
section
mm
stain
hematoxylin
eosin
light
microscopi
three
mice
group
examin
plasma
leakag
mice
measur
use
describ
previous
method
mice
administ
singl
intraven
inject
evan
blue
dye
min
lethal
dose
challeng
lt
experiment
cours
includ
h
fig
h
fig
lt
treatment
mgkg
mice
kill
tissu
sampl
collect
minc
incub
formamidewat
h
c
concentr
dye
determin
use
standard
curv
evan
blue
formamid
spectrophotomet
hitachi
japan
clot
time
analysi
plasma
recalcif
clot
time
measur
describ
previous
approxim
h
lethal
dose
lt
treatment
mgkg
blood
sampl
mice
collect
retroorbit
venou
plexu
use
plain
microhematocrit
capillari
tube
thermo
fisher
scientif
taiwan
taipei
taiwan
collect
polypropylen
tube
eppendorf
fisher
scientif
contain
anticoagul
acidcitratedextros
solut
acd
mm
citric
acid
mm
sodium
citrat
mm
dextros
plateletpoor
plasma
ppp
prepar
centrifug
g
min
ppp
centrifug
min
g
remov
contamin
cell
plasma
plasma
clot
induc
stir
condit
rpm
c
aggregomet
sienco
inc
wheat
ridg
co
ad
volum
prewarm
mm
cacl
solut
equal
volum
plasma
silicon
tube
time
second
need
clot
determin
analyz
effect
vitro
treatment
pselfc
mgl
lt
mgl
dosag
approxim
equival
vivo
mous
treatment
calcul
use
blood
volum
compris
total
bodi
weighton
recalcif
clot
time
mous
plasma
collect
healthi
wildtyp
mice
analyz
min
treatment
analyz
effect
vitro
treatment
mous
plasma
collect
h
pselfc
mgkg
lt
treatment
mgkg
treatment
isotyp
control
ig
mgkg
pa
mgkg
use
control
group
analyz
blood
paramet
hematocrit
platelet
count
liver
function
blood
plasma
sampl
mice
collect
retroorbit
venou
plexu
use
method
describ
previou
clot
time
section
experiment
cours
includ
h
fig
lt
treatment
mgkg
hematocrit
platelet
count
mice
measur
use
hematolog
analyz
sysmex
liver
function
analyz
detect
circul
aspart
aminotransferas
ast
liver
cell
specif
express
enzym
level
clinic
biochemistri
analysi
system
coba
integra
roch
microparticl
prepar
flow
cytometri
remov
blood
cell
includ
platelet
centrifug
mous
microparticl
mp
purifi
plasma
sampl
ultracentrifug
g
h
addit
mm
ethylenediaminetetraacet
acid
edta
prevent
clot
mp
resuspens
calciumfre
tyrod
buffer
mm
nacl
mm
kcl
mm
mgcl
mm
nah
po
mm
dextros
bovin
serum
albumin
bsa
mm
hepe
ph
mp
prepar
follow
antibodi
label
flow
cytometri
analysi
determin
mp
count
plasma
refer
bead
known
mp
count
polystyren
latex
bead
sigmaaldrich
mix
respect
plasma
sampl
unknown
mp
count
mp
count
plasma
sampl
analyz
use
ratio
bead
known
mp
unknown
fig
determin
rel
level
spsel
mpbound
nonmpbound
form
elisa
mp
pellet
obtain
ultracentrifug
resuspend
calciumfre
tyrod
buffer
plasma
volum
use
ultracentrifug
addit
plasma
sampl
dilut
fold
use
tyrod
buffer
elisa
rel
spsel
level
plasma
total
mp
fraction
mp
mppoor
plasma
fraction
mppp
plasma
supernat
ultracentrifug
determin
analyz
surfac
protein
express
mous
mp
flow
cytomet
facscalibur
bd
bioscienc
ca
use
fluoresc
antitf
antibodi
purchas
abcam
cambridg
mous
macrophagelik
cell
line
atcc
maintain
dulbeco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
use
cytotox
analysi
replac
serum
free
medium
cell
well
challeng
lt
ngml
lf
c
ngml
pa
cell
cultur
dish
without
addit
treatment
antipa
neutral
antibodi
bsa
pselfc
mgml
respect
three
hour
treatment
level
viabl
cell
analyz
use
kit
roch
diagnost
taipei
taiwan
accord
manufactur
instruct
analysi
principl
base
reduct
tetrazolium
salt
formazan
cellular
dehydrogenas
viabl
cell
cell
number
proport
level
yellow
formazan
format
measur
nm
rel
number
viabl
cell
calcul
accord
standard
curv
plot
valu
serial
dilut
cell
mean
standard
deviat
quantifi
data
calcul
use
microsoft
offic
excel
sigmaplot
spss
comparison
group
nonparametr
data
perform
use
oneway
analysi
varianc
follow
bonferronicorrect
test
univari
kaplanmei
analysi
use
compar
differ
surviv
rate
differ
treatment
group
p
valu
calcul
logrank
test
perform
determin
statist
signific
onlin
applic
surviv
analysi
lifespan
assay
http
sbipostechackroasi
also
use
probabl
type
error
equal
determin
threshold
statist
signific
potenti
conflict
interest
disclos
